Euglycemic ketoacidosis following a single dose of empagliflozin
Toxicology Communications · 2017
DOI: 10.1080/24734306.2017.1367078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicology Communications, 2017. Verfasst von Muhammad Masood Khalid und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have recently joined the therapeutic armamentarium for the treatment of diabetes mellitus. SGLT-2 inhibitors, as monotherapy or in combination with other medications, have a favorable effect on hemoglobin A1C concentrations. However, a growing number of reports have described ketoacidosis as a complication following prolonged SGLT-2 inhibitor therapy. We report a case of SGLT-2 inhibitor associated ketoacidosis in a patient following a single first dose of empagliflozin.
Zitieren
APA
Khalid, M. M., Vearrier, D. J., & Greenberg, M. I. (2017). Euglycemic ketoacidosis following a single dose of empagliflozin. Toxicology Communications. https://doi.org/10.1080/24734306.2017.1367078
Vancouver
Khalid MM, Vearrier DJ, Greenberg MI. Euglycemic ketoacidosis following a single dose of empagliflozin. Toxicology Communications. 2017. doi:10.1080/24734306.2017.1367078
BibTeX
@article{Khalid2017,
author = {Khalid, Muhammad Masood and Vearrier, David J. and Greenberg, Michael I.},
title = {Euglycemic ketoacidosis following a single dose of empagliflozin},
journal = {Toxicology Communications},
year = {2017},
doi = {10.1080/24734306.2017.1367078}
}
EUVIMED